Prestige Consumer Healthcare Completes Breathe Right Brand Acquisition
I'm LongbridgeAI, I can summarize articles.Prestige Consumer Healthcare completed the $1.045 billion acquisition of the Breathe Right brand from Foundation Consumer Healthcare on June 12, 2026. Funded via cash and a new Term Loan Credit Agreement, the deal makes Breathe Right Prestige's largest brand, expanding its presence in the nasal strip category. The transaction includes amended credit facilities to support integration and future acquisitions like LaCorium Health.
Prestige Consumer Healthcare ( (PBH) ) has issued an update.
Prestige Consumer Healthcare Inc. completed the acquisition of the Breathe Right brand and certain other brands from Foundation Consumer Healthcare on June 12, 2026, for $1.045 billion in cash, or about $900 million net of anticipated tax benefits. Breathe Right, created in the 1990s and the No. 1 brand in the nasal strip category, will become Prestige’s largest brand and extend the group into a new product category.
To fund the deal, Prestige and subsidiary Prestige Brands entered a new $1.045 billion Term Loan Credit Agreement on June 12, 2026, alongside an uncommitted $95 million second-draw option tied to the planned LaCorium Health acquisition and capacity for additional uncommitted borrowings. The company also amended and upsized its asset-based revolving credit facility to $225 million and extended its maturity, moves that significantly expand financial firepower while layering in standard covenants, security packages and leverage-based prepayment provisions relevant for lenders and shareholders monitoring balance sheet risk.
Prestige financed the Breathe Right transaction with a mix of existing cash and the new Term Loan B, and now holds a larger, more concentrated flagship brand that could reshape its revenue mix and competitive footing in consumer healthcare. The strengthened debt facilities, including the amended ABL line, position the company to integrate the Breathe Right business and pursue the LaCorium acquisition, though they also increase reliance on secured borrowing and ongoing compliance with covenants and leverage thresholds.
The most recent analyst rating on (PBH) stock is a Buy
with a $72.00 price target.
To see the full list of analyst forecasts on Prestige Consumer Healthcare stock,
see the PBH Stock Forecast page.
Spark’s Take on PBH Stock
According to Spark, TipRanks’ AI Analyst, PBH is a Neutral.
The score is supported by strong, consistent cash generation and resilient margins alongside an improved leverage profile. It is held back by a sharply negative technical setup (price well below key moving averages with bearish momentum) and a cautious near-term outlook with supply-chain-driven volatility despite modest FY27 growth and solid free-cash-flow guidance.
To see Spark’s full report on PBH stock,
click here.
More about Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc. is a branded consumer healthcare company that markets, sells, manufactures and distributes over-the-counter healthcare products to retail outlets across the U.S. and Canada, Australia and select international markets. Its diversified portfolio spans women’s health, pain relief, eye care, oral care, motion sickness, digestive health, pediatric, dermatological and nasal and sinus care categories, including flagship brands such as Monistat, Summer’s Eve, Clear Eyes, Dramamine, Fleet and others.
The company’s portfolio now also includes Breathe Right nasal strips, which become its largest brand and mark an expansion into the nasal strip category. Prestige focuses on non-prescription, consumer-facing healthcare brands that hold strong positions in niche categories and channels, supporting its strategy of acquiring and scaling recognizable, category-leading products in North America and abroad.
Average Trading Volume: 661,541
Technical Sentiment Signal: Sell
Current Market Cap: $2.27B
For a thorough assessment of PBH stock, go to TipRanks’ Stock Analysis page.